報價延遲最少15分鐘:2026/10/20 00:09 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.33 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.43/--
|
|
企業價值
117.23M
|
| 資產負債 |
|
每股賬面淨值
-1.79
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure. |
